Who are STEQEYMA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Stelara, PYZCHIVA, OTULFI, WEZLANA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ustekinumab-stba.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-01 · How we verify

STEQEYMA — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

STEQEYMA (USTEKINUMAB-STBA) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interleukin-12 Antagonist [EPC]. Area: Other.

marketed Interleukin-12 Antagonist [EPC] p40 protein subunit of IL-12 and IL-23 Other Live · refreshed every 30 min

Target snapshot

STEQEYMA (USTEKINUMAB-STBA) — CELLTRION, INC.. Ustekinumab binds to the p40 subunit of IL-12 and IL-23, disrupting their signaling and reducing inflammation.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
STEQEYMA TARGET	USTEKINUMAB-STBA	CELLTRION, INC.	marketed	Interleukin-12 Antagonist [EPC]	p40 protein subunit of IL-12 and IL-23
Stelara	ustekinumab	Johnson & Johnson	marketed		p40 protein subunit of IL-12 and IL-23
PYZCHIVA	USTEKINUMAB-TTWE	SAMSUNG BIOEPIS CO LTD	marketed	Interleukin-12 Antagonist [EPC]
OTULFI	USTEKINUMAB-AAUZ	FRESENIUS KABI USA	marketed	Interleukin-12 Antagonist [EPC]
WEZLANA	USTEKINUMAB-AUUB	AMGEN INC	marketed	Interleukin-12 Antagonist [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interleukin-12 Antagonist [EPC] class)

AMGEN INC · 1 drug in this class
CELLTRION, INC. · 1 drug in this class
FRESENIUS KABI USA · 1 drug in this class
SAMSUNG BIOEPIS CO LTD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). STEQEYMA — Competitive Intelligence Brief. https://druglandscape.com/ci/ustekinumab-stba. Accessed 2026-06-01.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab